Description
JARDIANCE DUO is indicated as an adjunct to diet and exercise to improve glycaemic control in adult patients with type 2 diabetes mellitus: when treatment with both empagliflozin and metformin is appropriate (see Pharmacology: Pharmacodynamics: Clinical Trials under Actions and Dosage & Administration).
Inadequately controlled with metformin or empagliflozin alone.
Inadequately controlled with empagliflozin or metformin in combination with other glucose- lowering products including insulin.
Prevention of cardiovascular events: Empagliflozin is indicated in adults with type 2 diabetes mellitus and established cardiovascular disease to reduce the risk of cardiovascular death (see Pharmacology: Pharmacodynamics: Clinical Trials under Actions).
The dosage should be individualised on the basis of the patient’s current regimen, effectiveness, and tolerability. The maximum recommended daily dose of JARDIANCE DUO is 25 mg of empagliflozin and 2000 mg of metformin.
Treatment naΓ―ve patients:Β The recommended starting dose is 5 mg/500 mg twice daily. If additional glycaemic control is required, adjust dosing based on effectiveness and tolerability while not exceeding the maximum recommended daily dose of 25 mg empagliflozin and 2000 mg metformin.